Clinical Trials
2 trialsNCT01371981 2026-06-02
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 3 Completed
NCT02066181 2023-06-07
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
National Cancer Institute (NCI)
Phase 3 Completed